Steven A. Kriegsman
Chairman and Chief Executive Officer
Mr. Kriegsman has been CytRx Corporation's President and Chief Executive Officer since 2002 and its Chairman since 2014. He also served as a director of Galena Biopharma, Inc. (Nasdaq: GALE) and Chairman of Galena's Compensation and Transaction Committees. He previously served as Director and Chairman of Global Genomics from June 2000. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences, and Maxim Pharmaceuticals. Mr. Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors' College. Mr Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the company has since been sold). In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University and New York University. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
John Y. Caloz
Chief Financial Officer
Mr. Caloz has an accomplished history of providing senior financial leadership in the life sciences sector, including as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, a medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
Shanta Chawla, M.D.
Senior Vice President, Drug Development
Dr. Chawla joined CytRx in 2014 as our Vice President of Clinical Development. For 11 years prior to joining us, she managed both oncology and non-oncology clinical trials at Spectrum Pharmaceuticals in Irvine, CA. Dr. Chawla oversaw the development of belinostat (a pan HDAC inhibitor), which was approved by the FDA and is marketed as a second line therapy for T-cell lymphoma. On June 13, 2017, Dr. Chawla was promoted to Senior Vice President – Drug Development, to lead our clinical and regulatory activities. Dr. Chawla did her residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania and an internship at Albert Einstein Medical Center. She later ran a successful internal medicine practice in Levittown, Pennsylvania.
David J. Haen
Vice President, Business Development and Investor Relations
Joined CytRx in October 2003 as Director of Business Development and was promoted to Vice President of Business Development in December 2007. Since 2013, he also serves as our Vice President of Investor Relations. He graduated Cum Laude from Loyola Marymount University in Business and Communications. Mr. Haen assists in negotiating strategic alliances, mergers and acquisitions, and in-licensing and out-licensing of product opportunities.
Vice President, Drug Discovery
Dr. Kratz is a medicinal chemist with more than 25 years of pertinent experience in the preclinical development of anticancer drugs, prodrugs and protein conjugation chemistry and profound knowledge of translational research from the laboratory to the clinic. He has successfully transferred aldoxorubicin, CytRx clinical lead compound, from bench to bedside that is based on an innovative drug delivery platform exploiting circulating albumin as a tumor-specific drug carrier. Felix Kratz graduated in Chemistry from the University of Heidelberg with Magna Cum Laude. Prior to joining CytRx Corporation he established the Division of Macromolecular Prodrugs at the Tumor Biology Center Freiburg. He serves on the Editorial Board for Bioconjugate Chemistry, Current Medicinal Chemistry, Current Bioactive Compounds, and Pharmacology & Pharmacy and has authored approximately 260 scientific publications, book articles and proceedings and is the inventor of over 20 patents and patent applications. As Vice President he heads the CytRx Drug Discovery Branch located in the Innovation Center Freiburg, Germany.